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Abstract
Background: Increased IL-18 serum levels have been associated with diabetes type 2, metabolic syndrome and
the severity of atherosclerosis. The present study investigated the presence and influence of IL-18 genetic variants
on gene- and protein expression in stable coronary artery disease (CAD) patients.
Methods: The +183 A/G (rs 5744292), -137 G/C (rs 187238) and -607 C/A (rs 1946518) polymorphisms were
determined in 1001 patients with angiographically verified stable CAD, and in 204 healthy controls. IL-18 gene-
expression was measured in circulating leukocytes in 240 randomly selected patients. Circulating IL-18 and IL-18
binding protein levels were measured immunologically in all patients.
Results: The +183 G-allele associated significantly with lower serum levels of IL-18 (p = 0.002, adjusted for age, glucose,
body mass index and gender) and a 1.13- fold higher IL-18 gene-expression (p = 0.010). No influence was observed for
the -137 G/C and -607 C/A polymorphisms. The IL-18 binding protein levels were not influenced by IL-18 genotypes. IL-
18 levels were significantly higher in men as compared to women, and in patients with diabetes type 2 and metabolic
syndrome compared to those without (p ≤ 0.001, all). The reduction in IL-18 levels according to the +183 G-allele was
3-4 fold more pronounced in diabetes and metabolic syndrome as compared to unaffected patients.
Finally, the +183 AA genotype was more frequent in patients with hypertension (p = 0.042, adjusted for age, body
mass index and gender).
Conclusion: The reduction in serum IL-18 levels across increasing numbers of +183G-alleles was especially
apparent in patient with diabetes type 2 and metabolic syndrome, suggesting a beneficial GG genotype in relation
to cardiovascular outcome in these patients.
Clinical Trial Registration Number: ClinicalTrials.gov: NCT00222261
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Introduction
With the knowledge that atherosclerosis is influenced by
an inflammatory process, IL-18 is one of the inflamma-
tory biomarkers that lately has been in focus amongst
researchers in cardiovascular disease (CVD). Being a
member of the IL-1cytokine family and a pleiotropic
pro-inflammatory cytokine, the molecule plays an
important role in the inflammatory cascade [1]. IL-18 is
also known as an interferon gamma (IFNg) - inducing
factor [2]. After being cleaved by Caspase-1, the biologi-
cally active molecule is secreted and may be neutralized
by a naturally occurring high-affinity IL-18 binding pro-
tein (IL-18 BP), modulating IL-18s’ interaction with the
IL-18 receptor (IL-18R) [3,4]. The binding of the free
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unbound IL-18 molecule to the a-chain of the cell-
bound heterodimer IL-18R is required for signal trans-
duction, mediated by the b-chain [5]. The downstream
activation enhances the maturation of T-cells and nat-
ural killer cells and the production of cytokines, chemo-
kines, cell-adhesion molecules, IFNg and matrix
metalloproteinases (MMPs), among other effects [1,6].
Both IL-18 and its receptor are expressed in active
macrophages, endothelial cells and vascular smooth
muscle cells and increased IL-18 expression has also
been demonstrated in atherosclerotic plaques [7,8].
Elevated circulating levels of Il-18 have been shown
associated with atherosclerotic lesions, diabetes type 2
(T2DM), metabolic syndrome (MetS), hypertension
(HT), and a worse prognosis in coronary artery disease
(CAD), although with conflicting results [9-13].
The levels of IL18 are influenced by many factors of
which genetic polymorphisms may contribute. Recent
studies have shown that some genetic variants of IL-18
may influence the risk and prognosis of CVD as well as
modifying the IL-18 expression and circulating levels of
IL-18, although the available genetic data suffers from
disparity [14-18].
To further extend the knowledge and the importance of
IL-18 gene variants, we aimed in the present study to inves-
tigate the frequencies of the 3’untranslated region (UTR)
+183 A/G and the promoter -137 G/C and -607 C/A IL 18
polymorphisms in a large population of stable CAD. Their
influence on IL-18 levels, and gene expression in circulat-
ing leukocytes as well as their distribution in subgroups of
patients were assessed. To explore IL-18 activity over its
endogenous antagonist, levels of IL-18 BP were evaluated
accordingly in the same cohort. Our hypotheses were that
the genetic polymorphisms would translate into variable
levels of IL-18 and possibly also IL-18 BP, and further be
differently distributed in subgroups of CAD.
We have in the present study demonstrated a signifi-
cant association between G- allele of the +183 A/G
polymorphism and lower circulating IL-18 levels, which
specifically was present in patients with T2DM and
MetS. The frequency of the +183 AA genotype was
higher in CAD patients with HT, but without any rela-
tion to CAD itself.
Methods
Study population
A total of 1001 patients (97% Caucasians) with stable
CAD, all angiographically verified, enrolled in the ASCET
trial [19] and 204 healthy individuals (mean age 55 years,
28% females, all Caucasians) were studied for the selected
IL-18 polymorphisms. The healthy individuals were
included after an interview, clinical examination, and a
near-maximum exercise bicycle electrocardiogram to rule
out any clinical evidence for cardiovascular disease.
Circulating IL-18 and IL-18 BP levels were measured in all
patients and IL-18 gene-expression was analyzed in a
cohort of 240 randomly selected patients in the CAD
group.
The study was approved by the Regional Ethics Com-
mittee and all patients gave their written informed con-
sent to participate. The ASCET study is registered at
the website; clinicaltrials.gov, identification number:
NCT00222261.
Clinical subgroups
Within the CAD population, previous myocardial infarc-
tion (MI) was recorded by patients’ medical files and
HT was defined as previous diagnosed and treated HT.
Diabetes included individuals with treated T2DM and/
or fasting glucose > 7.0 mmol/L and MetS was defined
according to the American Heart Association/National
Heart, Lung and Blood Institute [20]. Smoking habits
were recorded as current smokers or not. Ex-smokers
were included as non-smokers if they had quit smoking
≥ 3 months ago.
Blood collection
In fasting conditions between 8.00-10.00 a.m., blood
samples were collected and prepared for routine ana-
lyses (lipids, glucose, HbA1c) by use of convential meth-
ods, and for determination of IL-18 and IL-18 BP along
with DNA and RNA extraction.
Genotyping
DNA was extracted from EDTA whole-blood by using
the MagNA Pure LC DNA Isolation kit on the MagNA
Pure LC Instrument (Roche Diagnostics, Germany).
Genotyping of the promoter polymorphisms -137 G/C
(rs187238) and -607C/A (rs1946518) were performed
using allele specific primers and probes included in the
TaqMan® SNP Genotyping Assays; the C_11655953_10,
C_ 2898460_10, respectively (Applied Biosystems, Foster
City, CA, USA). The genotyping of the 3’UTR +183A/G
polymorphism (rs5744292) was performed using a Cus-
tom Design Assay manufactured by Applied Biosystems’
The Custom TaqMan® Assays Service. Allelic discrimi-
nations for all three polymorphisms were performed by
the ABI Prism 7900 HT Sequence Detection system
along with the TaqMan® Genotyping Master Mix
(Applied Biosystems). About 5% of the samples were
repeated, with 100% concordance. For the +183 A/G
SNP assay, samples with verified genotype were
included, kindly provided by Dr. Laurence Tirét, Faculté
de Médicine, Paris, France.
Gene-expression
Total RNA was extracted from PAXgene® Blood RNA
tubes, by using the PAXgene® Blood RNA Kit
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(PreAnalytix, Qiagen GmbH, Germany), including an
extra cleaning step (RNeasy®MinElute® Cleanup Kit,
Qiagen). Total RNA (range 200-800 ng/μL) was rever-
sely transcribed in a total volume of 20 μl, using the
Omniscript® RT Kit (Qiagen), Oligos (dTs) and Rnase
Inhibitor (Applied Biosystems). IL-18 mRNA levels were
determined by real-time PCR on the ViiA™ 7 Real
Time PCR System (Applied Biosystems), including the
TaqMan® Gene Expression Assay (HS00155517_m1)
and TaqMan® Fast Universal PCR Master Mix (2X) No
AmpErase® UNG (Applied Biosystems). The IL-18
mRNA levels were normalized to b-2-microglobulin
(HS99999907_m1, Applied Biosystems) and fold expres-
sion (relative quantification using the ΔΔCt method)
was determined in relation to a reference sample, as
previously described [21].
Measurements of IL-18 and IL-18 BP
Serum concentrations of IL-18 and IL-18 BP were deter-
mined using the Human IL-18 ELISA kit (Medical Bio-
logical Laboratories, Naka-ku Nagoya, Japan) and the
Human IL-18 BP ELISA kit (R&D Systems Europe,
Abingdon, Oxon, UK), the latter measuring isoenzyme a
of the IL-18 BP. Whether the IL-18 assay measures the
free IL-18 molecule and/or IL-18 bound to IL-18 BP
cannot be clarified by the manufacturer. The intra- and
inter-assay coefficients of variation for IL-18 were 2.1%
and 8.1%, respectively, and for IL-18 BP, 8.8% and 4.2%.
Statistics
The Chi square test was used to test for deviation from
Hardy-Weinberg equilibrium (HWE). Group compari-
sons were performed by Kruskal-Wallis test and Mann-
Whitney test when appropriate for continuous data and
Chi square test for categorical data. For correlation ana-
lysis, Spearman’s Rho was applied. A logistic regression
model was used to adjust for potential covariates in the
association between genotypes and clinical subgroups, i.
e. if significant in univariate comparisons. To adjust for
relevant covariates in the association between genotypes
and phenotypes, a linear regression model was used. A
two-tailed probability test of 0.05 or less was considered
statistically significant. Exact p-values are given, except
when p > 0.2. All statistical analyses were performed by
SPSS 16.0 (SPSS Inc).
Results
Characteristics of the CAD population are shown in
Table 1. All patients were on aspirin, 20% were diagnosed
with T2DM and 24% with MetS, 44% had previously suf-
fered MI, 56% were treated for HT, and 22% were
women. The +183 A/G and -607 C/A polymorphisms
were successfully analyzed in 996 individuals and the
-137 G/C in 995, and further in all controls (n = 204).
Frequencies of IL-18 polymorphisms
The obtained frequencies of the +183 A/G, -137 G/C
and -607 C/A polymorphisms are in line with previous
reports and no deviation from HWE was observed,
except for deviation in controls for the +183 A/G poly-
morphism. As shown in Table 2, frequencies of the
polymorphisms were not differently distributed in CAD
patients and controls. We observed two stable genotype
combinations in both cohorts; the +183 GG genotype
was always associated with wild-types of the two promo-
ter polymorphisms, whereas the -137 CC and -607 AA
genotypes were always connected with the +183 wild-
type (AA).
Serum IL-18 and IL-18 BP concentrations in relation to IL-
18 genotypes
The +183 A/G polymorphism associated significantly
with IL-18 levels in the total CAD population, with
lower levels across increasing numbers of G-alleles (p <
0.0001), still significant after adjustments for age, glu-
cose, body mass index (BMI) and gender (p = 0.002)
(Table 3). When dividing IL-18 levels into quartiles, sig-
nificantly higher numbers of homozygous patients (GG)
in the lowest quartile was observed (p < 0.0001, for
Table 1 Characteristics of the CAD population (n = 1001)
Age (years, mean (range)) 62 (36-81)
Men/Women n (%) 783/218 (78/22)
Type 2 Diabetes Mellitus n (%) 200 (20)
Myocardial infarction n (%) 436 (44)
Hypertension n (%) 553 (56)
Metabolic syndrome n (%) 244 (24)
SBP (mmHg) 139.4 (19.3)
DBP (mmHg) 82.1 (9.7)
Current smokers n (%) 204 (20.4)
BMI (kg/m2) 27.9 (11.5)
Total cholesterol (mmol/L) 4.6 (1.0)
HDL cholesterol (mmol/L) 1.3 (0.4)
LDL cholesterol (mmol/L) 2.5 (0.8)
Triglycerides (mmol/L) 1.6 (1.1)
Fasting glucose (mmol/L) 6.0 (1.9)
IL-18 pg/mL 248.0 (195.3, 322.7)*
IL-18 BP pg/mL 23.2 (19.2, 28.2)*
HbA1c (%) 6.0 (0.9)
Medication %
Statins 98
Aspirin 100
b-Blockers 76
Nitrates 22
ACE inhibitors 26
Values are mean (SD) or number (proportions) if not otherwise stated
SBP: systolic blood pressure; DBP: diastolic blood pressure; BMI: body mass
index; ACE: angiotensin converting enzyme.
* Median levels (25- and 75 percentiles)
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trend) (Figure 1). IL-18 levels did not differ according to
the -137 G/C and -607 C/A genotypes in the total CAD
population. However, in men alone, the -607 A-allele
associated weakly with higher IL-18 levels as compared
to the -607 CC genotype (p = 0.053) (medians (25, 75
percentiles): 258 (207, 336) versus 246 (196, 313) pg/
mL), respectively, however, not statistically significant
when adjusted for covariates (p > 0.2). IL-18 BP levels
were significantly correlated to IL-18 levels (r = 0.31, p
< 0.0001). No differences in IL-18 BP levels according
to any of the investigated genotypes were observed.
IL-18 gene-expression
The clinical characteristics of the subpopulation in
which gene-expression was performed (n = 240), were
similar to that of the total CAD group, except for a
higher frequency of patients with T2DM in the subpo-
pulation (28% versus 20%).
The +183 G-allele induced a 1.13 fold increase in the
levels of IL-18 mRNA in circulating leukocytes (p =
0.010), whereas none of the promoter polymorphisms
influenced IL-18 gene-expression. The gene-expression
data did not differ between subgroups of CAD.
Neither circulating IL-18 levels nor the IL-18 BP levels
correlated to expression levels of the IL-18 gene (r =
-0.083, p = 0.2 and r = 0.15, p = 0.8, respectively).
Frequencies of IL18 polymorphisms in subgroups of CAD
When comparing the presence of HT in relation to the
+183 AA, AG and GG genotypes, a significant higher
frequency of the AA genotype was observed in HT-
patients (p = 0.034), still significant after adjustment
for age, BMI, and gender (p = 0.042). The +183 homo-
zygous mutant (GG) individuals were simultaneously
wild-types of both the -137 (GG) and -607 (CC) poly-
morphisms, and the homozygous of the -137 and -607
variant alleles in parallel (CC and AA, respectively)
were persistently wild-types (AA) of the +183 poly-
morphism. An assessment of the homozygous mutants
versus wild types of the polymorphisms revealed a
reduced risk for having HT when being +183 GG
homozygous with an OR of 0.50 (9 5% CI 0.29, 0.85, p
= 0.009), still significant after adjustments for covari-
ates (p = 0.010) (Figure 2A). Furthermore, an increased
risk for having HT was related to the presence of the
-137 CC and -607 AA genotypes combined, with an
OR of 1.66 (95% CI 0.98, 2.8, p = 0.055), however less
prominent after adjustment for the covariates (p =
0.069) (Figure 2B).
No other associations between the investigated poly-
morphisms and subgroups of CAD, i.e. T2DM, MetS,
previous MI and gender, were observed.
Table 2 Frequencies of the IL-18 polymorphisms in CAD
patients and controls
IL-18 Genotype CAD (%) Controls (%) p-value *
+183 A/G AA 543 (55) 114 (56)
AG 391 (39) 85 (42)
GG 62 (6) 5 (2)
G-allele frequency 0.259 0.234 > 0.2
-137 G/C GG 532 (53) 108 (53)
GC 394 (40) 82 (40)
CC 69 (7) 14 (7)
C-allele frequency 0.267 0.270 > 0.2
-607 C/A CC 364 (37) 74 (36)
CA 500 (50) 96 (47)
AA 132 (13) 34 (17)
A-allele frequency 0.384 0.403 > 0.2
* Mann-Whitney test, heterozygous and homozygous of the minor allele
pooled
Table 3 Serum Levels of IL-18 in relation to the IL-18
polymorphism in the total CAD population
Genotype Il 18 pg/mL* p-value †
+183 AA 260 (204, 336) <0.0001#
AG 236 (193, 310)
GG 211 (155, 284)
-137 GG 248 (198, 323) > 0.2
GC 245 (193, 316)
CC 270 (192, 368)
-607 CC 243 (190, 313) > 0.2
CA 249 (199, 322)
AA 251 (192, 360)
* Median levels (25- and 75 percentiles)
† Kruskal-Wallis test
# p = 0.002 after adjustments for age, glucose, BMI and gender
p < 0.0001 
Figure 1 Numbers of +183 homozygous (GG) according to
quartiles (Q) of IL-18 (pg/mL): Q1 < 195, Q2 = 196-248, Q3 =
249-323, Q4 > 324.
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Serum IL-18 and IL-18 BP concentrations in CAD
subgroups as related to IL-18 genotypes
In the total CAD population, significantly higher levels
of IL-18 were found in patients with T2DM and MetS
as compared to patients without (p ≤ 0.001, both). Addi-
tionally, higher IL-18 levels were observed in men as
compared to women (p < 0.0001) (Table 4.) No differ-
ence in IL-18 levels was observed in the previous MI
and HT subgroups and between smokers and non-smo-
kers. Further, in patients with MetS, the IL-18 BP levels
were slightly, but significantly elevated (p = 0.010).
Due to the strong association between the +183 A/G
polymorphism and circulating IL-18 levels (Table 3),
analysis of IL-18 levels in the subgroups (T2DM, Mets,
and gender) according to the +183 A/G polymorphism
were performed. The G-allele associated significantly
with lower IL-18 levels in patients both with and with-
out T2DM (p = 0.006 and p = 0.003, respectively) (Fig-
ure 3A), and in patients with and without MetS (p =
0.001 and p = 0.005, respectively) (Figure 3B). However,
in diabetics versus non-diabetics a significantly more
pronounced reduction in IL-18 levels in +183 GG-
p = 0.010 p = 0.069 
% 
A B 
Figure 2 The presence of HT according to IL-18 gene variants: The percentage of HT in homozygous individuals of major and minor alleles
of the +183 A/G polymorphism (A) and the -137 G/C polymorphism (B), versus non-HT patients. P-values are adjusted for age, body mass index
and gender. As the -607 AA genotype always is present when the -137 CC genotype exist, only the -137 CC genotype is presented in Figure 2B.
Table 4 Serum levels of IL-18 and IL-18 BP in relation to CAD subgroups
Disease Entities IL 18 pg/mL* p-value † IL 18 BP pg/mL* p-value †
MI + 252 (197, 327) > 0.2 23.5 (19.4, 28.5) 0.191
- 245 (194, 320) 23.0 (19.2, 28.2)
HT + 248 (198, 318) > 0.2 23.5 (19.5, 29.1) 0.066
- 248 (190, 327) 22.8 (18.9, 27.2)
T2DM + 259 (207, 364) 0.001 23.6 (19.6, 29.0) 0.163
- 244 (192, 311) 23.0 (19.2, 28.1)
MetS + 265 (217, 356) < 0.0001 24.1 (19.8, 29.3) 0.010
- 243 (188, 310) 22.8 (19.1, 28.0)
Men 256 (203, 329) < 0.0001 23.2 (19.3, 28.3) > 0.2
Women 221 (176, 290) 23.1 (18.9, 28.1)
Current Smokers + 252 (207, 323) > 0.2 23.0 (19.2, 27.1) > 0.2
- 247 (194, 323) 23.2 (19.3, 28.7)
* Median levels (25- and 75 percentiles)
† Mann-Whitney test
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subjects compared to AA subjects was observed (p =
0.02) (Figure 3A). In MetS patients versus non-MetS
patients this difference was even more pronounced (p =
0.003) (Figure 3B). The reduction in IL-18 levels across
+183 genotypes was significantly present in men (p <
0.0001), whereas no difference in the reduction between
gender was observed (p = 0.2) (Figure 3C).
Discussion
The main findings in the present study were the signifi-
cant association between the G-allele of the IL-18 +183
A/G polymorphism and lower circulating IL-18 levels,
which specifically was present in patients with T2DM
and MetS. The frequency of the +183 AA genotype was
higher in CAD patients with HT, but without any rela-
tion to CAD itself.
The +183 G-alleles’ influence on IL-18 levels shown in
our relatively large study of stable CAD patients is in
accordance with results from one previous study in a
similar population [15]. The polymorphisms’ functional
mechanism has not been clarified. As the location of the
+183 A/G polymorphism is in the 3’UTR of the gene,
an interference with mRNA stability or the translational
process is suggested, as well as an interaction with the
5’ end in regulating the transcriptional activity. Although
no difference in allelic degradation of mRNA and no
difference in expression of an upstream reporter gene
were found in functional experiments [17], these possi-
bilities cannot be excluded. The +183 A/G polymorph-
ism is reported to be in complete linkage disequilibrium
(LD) with the 5’UTR -105C/T polymorphism, both
being parts of 6 major haplotypes defined by 5 poly-
morphisms in the IL-18 gene [15]. It was shown that
the haplotype carrying the +183 G-allele was the one
associated with the lowest IL-18 levels [15], supporting
the polymorphisms’ functional role in lowering IL-18
levels.
The +183 polymorphism modified slightly the expres-
sion of the IL-18 gene in circulating leukocytes, with
higher mRNA levels related to the G-allele. This result
seem to present a discrepancy to the lower IL-18 circu-
lating levels, and also to previous gene-expression
results from lymphoblastoid cell-lines [17]. The
observed 1.13-fold increase may not be of biological sig-
nificance. Further, circulating leukocytes may not be the
main source contributing to circulating IL-18, although
IL-18 mRNA was shown to be constitutively expressed
in human peripheral blood mononuclear cells due to
lack of a destabilizing sequence in the 3’UTR of the IL-
18 gene [22]. A post-translational impact of the inflam-
masome and Caspase-1, in the cleavage of pro IL-18 to
its active secreted form, may contribute to the inconsis-
tency. The results may, nevertheless, also indicate a
compensatory reaction from the circulating inflamma-
tory cells.
We observed no influence of the -137 G/C and -607
C/A polymorphisms on circulating IL-18 levels or on
IL-18 gene expression. These two promoter polymorph-
isms have previously been associated with lower tran-
scriptional activity in in vitro studies [18,23,24].
B 
p1 = 0.006 p2 = 0.003 p 2 = 0.005 p1 = 0.001 
p = 0.02 p = 0.003 
p 2  > 0.2 p1 < 0.0001 
p = 0.2 
A C 
Figure 3 Effects of the +183 A/G polymorphism on IL-18 circulating levels in different CAD subgroups: Differences in the G-alleles’
lowering effects in patients with T2DM (A) and Mets (B) as compared to unaffected patients, and in men as compared to women (C). p1 and p2
values refer to trend analyses across genotypes. p-values refer to differences in changes between groups across genotypes.
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However, in a human population no association was
observed for the -137 G/C variant [23].
Significantly higher IL-18 levels were found in male
patients as compared to females. This gender difference
is to our knowledge novel information. In a recent
meta-analysis, in which nine of twelve studies included
both gender, the association between IL-18 and CVD
events was generalized to both gender [25]. However, an
increased IL-18 related risk of CV events in men war-
rant further investigation. Interestingly, an experimental
study performed in mice indicated that increased endo-
genous IL-18 production reduced survival only in the
male animals [26].
Increased IL-18 levels in patients withT2DM and MetS
have previously been reported, and our observations sup-
port these results [9,11,27-29]. The importance of IL-18
in MetS was also underlined in a review by Trøseid et al.
[30]. It was also recently shown increased IL-18 mRNA
expression in adipose tissue from MetS subjects com-
pared to non-MetS individuals [31]. We could further
demonstrate that the influence of the +183 A/G poly-
morphism was especially apparent in the T2DM and
Mets groups, suggesting a beneficial influence of the G-
allele in these patients. G-allele carriers have also been
reported to have reduced frequency of MetS and the sub-
sequent IL-18 levels were suggested to be of genetic ori-
gin [32]. Although the frequency of the +183 G-allele
was not differently distributed in MetS and T2DM
patients as compared to the unaffected patients in the
present study, an association is still feasible.
The observed risk of having HT was significantly
affected by the presence of the combined genotypes of the
three polymorphisms investigated (+183 A/G, -137 G/C
and -607 C/A). The +183 GG genotype (in combination
with -137 GG and -607 CC) was associated with a 50%
lower HT risk, whereas the +183 AA, in combination with
-137 CC and -607 AA, was associated with a 70% higher
risk. It should be emphasized that our stable CAD patients
with HT did not present higher IL-18 levels, which might
be due to their treatment regimen. Nevertheless, as the
combined genotypes in the total population were asso-
ciated with lower and higher circulating IL-18 levels,
respectively, a related mechanism is plausible.
An inflammatory state accompanied by the A-allele of
the +183 polymorphism may consequently induce a
cumulative increased risk for HT. Genotypes are fixed
during life-time and a pro-inflammatory state initiated
early in life may consequently lead to development of
HT over time in these genotype-specific patients. We
have previously shown that arterial stiffness was asso-
ciated with both elevated levels of IL-18 and elevated
systolic blood pressure in MetS patients [33]. Chronic
elevated levels of IL-18 may lead to a persistently
increased expression of IL-18 inducible cytokines
downstream of the NF-B/AP-1 signal pathway, i.e.
IFNg and MMPs [34,35], which are of importance for an
inflammatory state in atherosclerosis in general and for
arterial remodeling, important in HT. HT has on the
other hand been shown to induce an upregulation of IL-
18 through b2-adrenergic receptor stimulation in
endothelial cells. Thus, a positive feed-back mechanism
has been suggested [36].
In the attempt to sort out the role of IL-18 BP in reg-
ulating IL-18 levels, our results were not clarifying. The
levels of IL-18 and IL-18 BP were significantly corre-
lated, and as the expression of IL-18 BP has been shown
to be markedly up-regulated by IFNg, a negative feed-
back mechanism on IL-18 activity has been suggested
[37]. The interrelated values may also be a consequence
of the methodology used in measuring the two markers.
The results indicate that the utilized IL-18 assay also
measures IL-18 in complex with IL-18 BP and not only
the free IL-18 molecule, also stated by others [38,39]. As
the manufacturer cannot clarify what the assay exactly
measures, no valid conclusion can be drawn.
Limitations
The control group is small and seven years younger
than the patient population, which may limit the statisti-
cal value of these results. The controls were, however,
only included in the gene-analysis. As the +183 A/G
polymorphism deviates from HWE in controls, probably
due to small sample size, the observed related frequen-
cies should be carefully interpreted.
In summary, the +183 A/G polymorphism induced
lower IL-18 levels consistently and significantly, and has
conceivably a functional role in regulating the transcrip-
tional and/or the translational process. The beneficial
+183 GG genotype was especially apparent in relation to
IL-18 levels in MetS and T2DM patients. The modified
risk for HT according to the different genotypes indi-
cates an importance of this gene in HT patients, possi-
bly through IL-18 levels. As HT, MetS and T2DM are
associated with worse prognosis in CVD, the regulatory
mechanisms of IL-18, especially through the +183 A/G
polymorphism should be further explored.
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